Skip to main content

Affinity Asset Advisors, LLC

Position in DNTH — Dianthus Therapeutics, Inc. /DE/

CIK 1773195 NEW YORK, NY

Position in DNTH

as of Mar 31, 2026 · filed May 14, 2026
Position Value
$29,372,000
+$24,632,850 QoQ
Shares Held
350,000
+204.3% QoQ
Ownership
0.640%
of shares outstanding
% of Portfolio
1.78%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in DNTH Over Time

Shares Held

Position Value (USD)

Derivatives in DNTH

reported options exposure · as of Mar 31, 2026
CallValue
$4,196,000
CallShares
50,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Affinity Asset Advisors, LLC holds $1,518,254,571 across 81 Biotechnology names. DNTH ranks #15 (1.9% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in DNTH

Export CSV
4 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $4,196,000 50,000
2026-03-31 $29,372,000 350,000
2025-12-31 $4,739,150 115,000
2025-09-30 $10,313,635 262,100